Materials and Methods: This two-center, retrospective trial evaluated the treatment results of preterm infants who underwent LP for ROP between 2013 and 2019 and who were also followed for at least 1 year following LP.

Results: Four hundred thirty-seven eyes of 225 infants were included in the study. Of the eyes treated with LP, 284 had type 1 ROP, 129 had type 2 ROP, and the remaining 24 eyes had aggressive posterior retinopathy of prematurity (APROP). After the initial LP, manifestations of ROP regressed completely in 397 (90.8%) eyes, whereas for 40 eyes (9.2%), additional treatment was required. Of these infants, 18 (45%) eyes underwent rescue intravitreal bevacizumab (IVB), while LP was applied at the posterior ridge of 16 (40%) eyes, and additional LP was applied in 6 (15%) eyes. Fourteen (58.3%) eyes with APROP and 26 (9.2%) eyes with type 1 ROP required additional treatments, and the difference between them was statistically signifi cant (p<0.001). After all follow-up and treatments, an unfavourable anatomic outcome was observed in 4 eyes (0.9%) at a corrected age of one year.

Conclusion: Near-confl uent LP is an effi cient treatment, in particular for infants with type 1 and type 2 ROP. However, the requirement of additional treatment following the initial LP is greater in infants with APROP. Keywords : Aggressive posterior retinopathy of prematurity (APROP), Type 1 retinopathy of prematurity (ROP), Type 2 retinopathy of prematurity, Laser photocoagulation (LP)